November 20, 2023
Astellas Pharma and Pfizer said on November 16 that their androgen receptor signaling inhibitor Xtandi (enzalutamide) has obtained US FDA approval as an earlier treatment option for certain patients with castration-sensitive prostate cancer (CSPC). The green light was given for...read more